Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001365
Status:
COMPLETED
Last Update Posted:
2006-07-13
First Post:
1999-11-03
Brief Title:
Dextromethorphan for the Treatment of Parkinsons Disease and Similar Conditions of the Nervous System
Sponsor:
National Institute of Neurological Disorders and Stroke NINDS
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
NMDA Receptor Antagonist Treatment of Neurodegenerative Disease
Status:
COMPLETED
Status Verified Date:
2000-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to determine whether dextromethorphan a drug commonly found in cough medicine is beneficial and safe for the treatment of Parkinsons disease and other diseases that might share biochemical abnormalities with Parkinsons disease
Patients with Parkinsons disease are missing the chemical neurotransmitter dopamine This occurs as a result of destructive changes in an area of the brain responsible for making dopamine the basal ganglia Rhythmical muscular tremors rigidity of movement shuffling footsteps droopy posture and a mask-like expression on the face characterize Parkinsons disease
Researchers believe that dextromethorphan may be able to safely modify psychomotor function of patients with Parkinsons Disease
Patients with Parkinsons disease are missing the chemical neurotransmitter dopamine This occurs as a result of destructive changes in an area of the brain responsible for making dopamine the basal ganglia Rhythmical muscular tremors rigidity of movement shuffling footsteps droopy posture and a mask-like expression on the face characterize Parkinsons disease
Researchers believe that dextromethorphan may be able to safely modify psychomotor function of patients with Parkinsons Disease
Detailed Description:
The ability of the putative excitatory amino acid receptor antagonist dextromethorphan to modify psychomotor function safely in patients with neurodegenerative disease will be evaluated using a modified double-blind placebo-controlled design Therapeutic activity will be rated at various doses by means of standard motor and cognitive performance scales Safety will be assessed at frequent intervals by clinical observation and laboratory tests
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 93-N-0183 | None | None | None |